MILL VALLEY, Calif. and NEW YORK, Dec. 3, 2025 /PRNewswire/ — The National Kidney Foundation (NKF), the nation’s leading nonprofit dedicated to the prevention and treatment of kidney disease, and inTandem Health, a pioneer in digital peer support solutions, today announced a strategic partnership to revolutionize the transplant experience for patients, living donors, and caregivers nationwide.
This first-of-its-kind collaboration combines NKF’s network of more than 200 trained peer mentors and national coordination team with inTandem’s state-of-the-art digital consumer experience platform, creating a turnkey solution for transplant centers. The partnership ensures that every patient and donor is automatically offered highly trained and trusted, one-to-one peer support at the right moment in their journey.
Meeting a Critical Need & CMS IOTA Goals
Every day in the United States, 13 people die waiting for a kidney transplant. Patients often face long wait times, emotional isolation, and uncertainty, while care teams are stretched thin. Together, NKF and inTandem are addressing these challenges by creating a scalable system of human connection and data-driven support.
This partnership directly advances CMS IOTA goals by:
Proven Impact
What This Partnership Delivers
For hospitals and transplant centers, the NKF–inTandem collaboration offers a turnkey, ready-to-launch solution that integrates seamlessly into existing workflows:
Leadership Perspectives
“By bringing together NKF’s unmatched mentor training and community and inTandem’s innovative Human Connect technology, we are creating a powerful new model of patient- and donor-centered care,” said Jessica Joseph, SVP Scientific Operations, National Kidney Foundation.
“This partnership represents a turning point in how we support patients and families,” said Paul Hoffman, CEO, inTandem Health. “Together with NKF, we’re making sure no patient or donor has to navigate the transplant journey alone—while giving hospitals the insights they need to improve retention, outcomes, and trust.”
“The CMS IOTA Model is all about outcomes, particularly reducing readmissions and improving care coordination,” said John Davis, former CEO of NKF and KDIGO, and inTandem Health Board Member. “Peer mentors can play a vital role in keeping patients informed, prepared, and adherent to care plans. They are a cost-effective extension of the care team, reducing staff burden while making a measurable impact on the metrics that matter most to hospitals.”
inTandem Health Board Leadership Supporting the Partnership
inTandem Health’s board includes nationally recognized leaders in kidney and hospital care who are actively guiding the NKF partnership. John Davis, former CEO of NKF and KDIGO, and Fred Brown, past chair of NKF, the American Hospital Association, and The Joint Commission, bring decades of experience in advancing patient-centered transplant care.
About the National Kidney Foundation
The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis and transplantation. For more information about NKF, visit www.kidney.org
About inTandem Health
inTandem Health is a digital health company transforming the transplant experience by connecting living donors, patients, and caregivers through a secure peer support platform. By addressing both emotional and practical needs, inTandem helps health systems improve outcomes, increase patient acquisition and retention, meet CMS IOTA goals, and deliver compassionate care at scale. Learn more at www.intandemhealth.net
SOURCE National Kidney Foundation
TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription…
Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January…
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern…
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard…
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the…